Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 1:37 PM ET


Company Overview of Theraclone Sciences, Inc.

Company Overview

Theraclone Sciences, Inc., a discovery-stage biotech company, develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. It provides In-Situ Therapeutic Antibody Rescue technology, which allows for the rapid testing of human antibodies to find those with exceptional biological functions and activities; and TCN-032, a recombinant human monoclonal antibody for the treatment of patients hospitalized with serious influenza. The company has antibody programs at preclinical and clinical development stage targeting serious medical conditions with a significant unmet medical need, including triple negative and endocrine treatment resistant HER-2 negative breast cancer...

1124 Columbia Street

Seattle Life Sciences Building

Suite 300

Seattle, WA 98104

United States

Founded in 2004





Key Executives for Theraclone Sciences, Inc.

Chief Executive Officer and Director
Age: 56
Founder and Member of Scientific Advisory Board
Chief Financial Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Theraclone Sciences, Inc. Key Developments

OncoResponse Will Use Theraclone's I-STAR Immune Repertoire Screening Technology

OncoResponse has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences, of Seattle, Washington. OncoResponse will use Theraclone's I-STAR immune repertoire screening technology to identify therapeutic antibodies against novel targets from immuno-oncology treated patients. I-STAR technology rapidly screens antibodies made by the human immune system to identify those with exceptional reactivity that may lead to cancer treatment development.

Theraclone Sciences, Inc. Presents at BioPharm America 2015, Sep-15-2015 04:00 PM

Theraclone Sciences, Inc. Presents at BioPharm America 2015, Sep-15-2015 04:00 PM. Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States. Speakers: Clifford J. Stocks, Chief Executive Officer and Director.

Wellcome Trust Selects Theraclone Sciences, Inc.'s I-STAR™ Technology to Identify Therapeutic Antibodies Against Ebola Virus

Theraclone Sciences, Inc. announced that its I-STAR™ Technology chosen by Wellcome Trust to identify Therapeutic Antibodies against Ebola Virus. The company will identify potential therapeutic antibodies against the Ebola virus utilizing the Company’s powerful human memory B-cell interrogation platform. The I-STARTM technology can rapidly screen antibodies from survivors of Ebola to uncover those with exceptional biologic activity that may lead to the development of a therapeutic antibody. BIO Ventures for Global Health was instrumental in forming a consortium of Ebola experts for the endeavor, and will collaborate with Theraclone on management of the project. To fund the initial screening and development efforts, Theraclone will receive up to $4.4 million in a Series C financing, which includes an investment from the Wellcome Trust along with existing investors.

Similar Private Companies By Industry

Company Name Region
NeuroVir Inc. United States
ParentPlus, LLC United States
Caribou Biosciences, Inc. United States
Inhibrx LLC United States
Integenx Acquisition Corp. United States

Recent Private Companies Transactions

Private Placement
April 24, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Theraclone Sciences, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at